<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01593631</url>
  </required_header>
  <id_info>
    <org_study_id>120506000</org_study_id>
    <nct_id>NCT01593631</nct_id>
  </id_info>
  <brief_title>Acid Lactase in Combination With Yoghurt Bacteria for Improvement of Lactose Digestion in Lactose Malabsorbers</brief_title>
  <official_title>A Combination of Yoghurt Bacteria and Acid Lactase From Aspergillus Oryzae Improves Lactose Digestion in Lactose Malabsorbers More Reliably Than Preparations Containing Acid Lactase or Yoghurt Bacteria Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vitacare Gmbh &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vitacare Gmbh &amp; Co. KG</source>
  <brief_summary>
    <textblock>
      Fermented dairy products, especially real Yoghurt, are often tolerated better by lactose
      malabsorbers than unfermented dairy products. The intake of dietary supplements containing
      acid Lactase derived from Aspergillus oryzae with lactose containing foodstuffs is known to
      reduce/alleviate symptoms of lactose intolerance in lactose malabsorbers. The study aims to
      compare the effect of the intake of a combination of yoghurt bacteria and acid lactase to the
      effect of yogurt bacteria or acid lactase alone on the lactose digestion in lactose
      malabsorbers. It is hypothized that the combination preparation will be more effective and/or
      will show a more reliable effect than the two mono-preparations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in hydrogen concentration in the breath (H2-exhalation breath test)</measure>
    <time_frame>Every 20 minutes for 4 hours</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Lactose Malabsorption</condition>
  <arm_group>
    <arm_group_label>2 billion lyoph. yoghurt bacteria</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3300 FCC acid lactase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>9000 FCC acid lactase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination of Substances of arm 1 and 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Acid lactase</intervention_name>
    <description>capsules cotaining 3300 FCC units of acid lactase</description>
    <arm_group_label>3300 FCC acid lactase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Acid lactase</intervention_name>
    <description>capsules containing 9000 FCC of acid lactase</description>
    <arm_group_label>9000 FCC acid lactase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lyoph. yoghurt bacteria</intervention_name>
    <description>capsules containing 2 billion lyoph. yoghurt bacteria</description>
    <arm_group_label>2 billion lyoph. yoghurt bacteria</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Acid lactase plus yoghurt bacteria</intervention_name>
    <description>Capsules containing 3300 FCC of acid lactase and 2 billion lyoph. yoghurt bacteria</description>
    <arm_group_label>Combination of Substances of arm 1 and 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules containing di-calcium-phosphate</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects of African or Asian origin.

          -  Older than 18 years

          -  Written informed consent

        Exclusion Criteria:

          -  Participation in a clinical study with a drug or a medical product withing the last 30
             days;

          -  Inability to comply with the study protocol;

          -  Allergy to milk protein;

          -  Intolerance against lactase preparations;

          -  Known metabolic or gastrointestinal diseases which affect the absorption, metabolism
             or excretion of food components except lactose maldigestion;

          -  Intake of drugs influencing resorption of food components or gastrointestinal
             motility;

          -  Surgery within the last three months which still affect the current status of health;

          -  Psychiatric diseases

          -  Epilepsia

          -  Risk for suicide

          -  Eating disorders, e.g. anorexia, bulimia

          -  Alcohol or drug abuse

          -  Legal incapacity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>tecura GmbH Medicine &amp; Biotechnics - Dept. of Clinical Research</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24118</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2012</study_first_submitted>
  <study_first_submitted_qc>May 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2012</study_first_posted>
  <last_update_submitted>May 7, 2012</last_update_submitted>
  <last_update_submitted_qc>May 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lactose malabsorption</keyword>
  <keyword>lactose intolerance</keyword>
  <keyword>lactose digestion</keyword>
  <keyword>lactose maldigestion</keyword>
  <keyword>acid lactase</keyword>
  <keyword>yoghurt bacteria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malabsorption Syndromes</mesh_term>
    <mesh_term>Lactose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

